OSI Pharmaceuticals
73
0
0
55
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
24.7%
18 terminated/withdrawn out of 73 trials
75.3%
-11.2% vs industry average
7%
5 trials in Phase 3/4
75%
41 of 55 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (73)
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
Role: collaborator
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
Role: collaborator
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Role: lead
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Role: lead
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Role: lead
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Role: collaborator
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Role: collaborator
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
Role: collaborator
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Role: collaborator
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
Role: collaborator
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
Role: collaborator
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Role: collaborator
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Role: collaborator
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Role: collaborator
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
Role: collaborator
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Role: collaborator
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Role: collaborator
Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
Role: collaborator
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Role: collaborator
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
Role: collaborator